Figure 2. Relieved red swollen joints and splenomegaly and decreased urine protein level in lupus mice after therapy. (a) Change trends of joint diameters and (b and c) comparisons of spleen weight and length in all induced groups. (d) Change in urine protein levels in PC, T, T+MP, and MP. (e) At week 32, urine protein was reduced in T, T+MP, and MP than in PC. MP: Methylprednisolone; ns: Not significant; PC: Pristane control; T: Tofacitinib; T+MP: Tofacitinib plus methylprednisolone; * p<0.05; ** p<0.01; *** p<0.001.